Posted on

Orvessa Hayes LLC Expands Cross-Border Investment and Business Network Across Asia

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) — Orvessa Hayes LLC, an American cross-border investment and business advisory firm, today announced the strategic expansion of its global network across key Asian markets. By combining its international investment research capabilities with the local insights and resources of high-net-worth partners, entrepreneurs, and industry leaders, the company is establishing a collaborative framework designed to unlock long-term cross-regional business opportunities.

By sf-admin
Posted on

ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026

Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria.

Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry.

In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories.

Oral Presentation Details
Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry
Session Title: Renal Cell Cancer and Novel Targets 
Session Number: 506
Track: Clinical Oncology
Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST
Location: Hall C
Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany

Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide
Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy
Session Number: 1505
Track: Cutting Edge Science
Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST
Location: Hall B
Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France

Meet the Expert Session
Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities
Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST
Location: ITM Booth #415, Hall X4
Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM

Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST.

177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use.

About the COMPETE Trial
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs.

About Ga-DPI-4452 (ITM-94)
Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use.

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

About Lumara Bio
Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com

ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com

By sf-admin
Posted on

MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence

Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet medical need, affecting more than 150 million women worldwide, for which no approved therapy presently addresses the underlying cause. The study results were presented in an oral session at the Annual Meeting of the International Continence Society (ICS) in Maastricht, the Netherlands, on October 7, 2026 [1].

By sf-admin
Posted on

First Digital签署最终协议:将成为上市公司，以构建智能体经济基础设施为主

FDUSD 的发行方First Digital已与CSLM Digital Asset Acquisition Corp III签订最终业务合并协议，以投前股权估值计，该协议对First Digital的估值为2.5亿美元。该公司累计交易量已超过四万亿美元。交易完成后，合并后的公司预计将成为纳斯达克上市公司 

FDUSD 的发行方First Digital已与CSLM Digital Asset Acquisition Corp III签订最终业务合并协议，以投前股权估值计，该协议对First Digital的估值为2.5亿美元。该公司累计交易量已超过四万亿美元。交易完成后，合并后的公司预计将成为纳斯达克上市公司

By sf-admin
Posted on

First Digital, 에이전틱 경제 인프라 구축을 위한 상장사 전환 확정 계약 체결

FDUSD(누적 거래량 4조 달러 이상 기록)를 운영하는 그룹 First Digital이 CSLM Digital Asset Acquisition Corp III와 First Digital의 가치를 투자 전 지분가치(pre-money equity) 기준 2억 5,000만 달러로 평가하는 사업결합 확정 계약을 체결했으며, 거래 종결 시 합병 후 통합법인은 나스닥 상장사가 될 것으로 예상됩니다 

FDUSD(누적 거래량 4조 달러 이상 기록)를 운영하는 그룹 First Digital이 CSLM Digital Asset Acquisition Corp III와 First Digital의 가치를 투자 전 지분가치(pre-money equity) 기준 2억 5,000만 달러로 평가하는 사업결합 확정 계약을 체결했으며, 거래 종결 시 합병 후 통합법인은 나스닥 상장사가 될 것으로 예상됩니다

By sf-admin